At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell ...

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...

A nurse practitioner discusses how breast cancer treatment can impact sexual health, and how nurses and APPs can guide ...

With many patients utilizing medical cannabis, it is important for nurses to be aware of potential drug-drug interactions, an expert said.

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...

The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of ...

With newer breast cancer treatments, it’s essential that nurses and APPs educate themselves and advocate for their patients.

Nurse navigators and APPs are key members of the multidisciplinary team who can lead and implement QI efforts to ensure timely and effective biomarker testing for patients with early-stage NSCLC.

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.

FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...

Surveyed individuals who identified as a racial or ethnic minority reported difficulties discussing cancer diagnosis and treatment. Typical stories shared about “going flat” after a mastectomy may not ...